Dapagliflozin increases pAMPK and reduces myocardial and renal NF-kB expression in preclinical models of short-term doxorubicin cardiotoxicity through MYD-188 and NLRP3 pathways
Anno:
2023
Background: Doxorubicin-mediated adverse cardiovascular events are among the leading causes of morbidity and mortality in breast cancer patients. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to be of therapeutic value in patients with type 2 diabetes, chronic kidney disease, and heart failure with reduced ejection fraction (HFrEF),…